OncoMatch/Clinical Trials/NCT06607692
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Is NCT06607692 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies Olaparib; 177Lu-DOTATATE for solid tumor cancer.
Treatment: Olaparib; 177Lu-DOTATATE — Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing somatostatin receptors (SSTR) (LuPARPed)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Radioligand therapy
Cancer type
Tumor Agnostic
Glioblastoma
Neuroblastoma
Meningioma
Neuroendocrine Tumor
Diffuse Intrinsic Pontine Glioma
Osteosarcoma
Biomarker criteria
Required: SSTR expression (SSTR-PET visual score ≥ 2 in majority of tumoral lesions)
Diagnosis: relapsed/refractory solid tumours with positive uptake on SSTR-PET (PET-CT or PET-MRI)... Patients with scores ≥ 2 in the majority of the tumoral lesions will be considered to have a positive SSTR-PET and will be therefore eligible for the trial.
Demographics
Prior therapy
Cannot have received: radiolabelled somatostatin analogue
Exception: no more than one previous treatment
Having received more than one previous treatment with other radiolabelled somatostatin analogues
Lab requirements
Blood counts
Hb ≥10 g/dl (transfusion allowed up to 24h prior); WBC ≥ 2500/μL; ANC ≥ 1000/μl; Platelets ≥ 100,000/μl (no transfusion in prior ≥7 days)
Kidney function
Serum plasma creatinine ≤ 1.5 x ULN OR eGFR ≥ 60 mL/min/1.73m2 (2009-Schwartz formula)
Liver function
Total bilirubin ≤ 1.5 x ULN (≤ 3.0 ULN if Gilbert's Syndrome); ALT or AST ≤ 3.0 ULN; Albumin >3.0 g/dL
Adequate organ function within 28 days prior to enrolment, as defined by: Hb ≥10 g/dl... WBC ≥ 2500/μL... ANC ≥ 1000/μl... Platelets ≥ 100.000/μl... Serum plasma creatinine ≤ 1.5 x ULN OR eGFR ≥ 60 mL/min/1.73m2... Total bilirubin ≤ 1.5 x ULN... ALT or AST ≤ 3.0 ULN... Albumin >3.0 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06607692 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiolabelled somatostatin analogue disqualifies patients from enrollment.
Does this trial require SSTR?
Yes, SSTR expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 18 years or younger and at least 3 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify